Key result
High cPLA2a expression was significantly associated with metastasis, advanced Enneking stage, and poor prognosis, serving as an independent prognostic biomarker in osteosarcoma.
Why the study?
Osteosarcoma patients with metastasis have dismal prognoses and lack effective target therapies, and the functions of cPLA2 in osteosarcoma have not been investigated.
Does cPLA2a expression correlate with metastasis and prognosis in osteosarcoma?
Observational (n=102)
Does cPLA2a expression correlate with metastasis and prognosis in osteosarcoma?
High cPLA2a expression is an independent prognostic biomarker for poor outcomes in osteosarcoma and promotes cell invasion via EMT.
Answers are grounded in this paper and cite their sources.
High cPLA2a expression may aid osteosarcoma risk stratification; leaves open validation and therapeutic targeting in prospective studies.
Osteosarcoma (OS) patients with metastasis have very dismal prognoses, and lack effective target therapies. Overexpression of cytosolic phospholipase A2 (cPLA2) has been shown to promote progression in several types of cancers, but its functions in OS have not been investigated. In our study, the expression of cPLA2a was detected with immunohistochemistry in 102 cases of OS. The clinical significance of cPLA2a was evaluated by analyzing its correlation with clinicopathological factors. The prognostic significance of cPLA2a was estimated by univariate and multivariate analysis. The oncogenic functions of cPLA2a on cell proliferation and invasion were investigated by MTT assay and tranwell assay respectively. Western blotting was applied to detect the markers of epithelial-mesenchymal transition (EMT) after silencing cPLA2a expression or inhibiting its activity by a specific antagonist. In our study, high expression of cPLA2a was significantly associated with metastasis and advanced Enneking stage. High cPLA2a expression was significantly associated with poor prognosis and it was an independent prognostic biomarker of OS. By silencing cPLA2a or inhibiting its activity by a specific antagonist, we demonstrated that cPLA2a promoted cell invasion of OS cells via inducing the EMT process. High cPLA2a expression was an independent prognostic biomarker of OS, and cPLA2a could promote OS cell invasion via inducing the EMT process, indicating that cPLA2a was an independent prognostic biomarker and may be an effective drug target for OS.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2019) conducted an observational in Osteosarcoma (n=102). High cPLA2a expression vs. Low cPLA2a expression was evaluated on Metastasis, advanced Enneking stage, and prognosis. High cPLA2a expression was significantly associated with metastasis, advanced Enneking stage, and poor prognosis, serving as an independent prognostic biomarker in osteosarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: